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Abstract  
Allograft transplantation into sensitised recipients with anti-donor antibodies results in 
accelerated antibody-mediated rejection (AMR), complement activation and graft thrombosis. 
We have developed a membrane-localizing technology of wide applicability that enables 
therapeutic agents including anticoagulants to bind to cell surfaces and protect the donor 
endothelium. We describe here how this technology has been applied to thrombin inhibitors to 
generate a novel class of drugs termed thrombalexins (TLN). Using a rat model of hyperacute 
rejection we have investigated the potential of one such inhibitor (TLN-1) to prevent acute 
antibody-mediated thrombosis in the donor organ. TLN-1 alone was able to reduce intragraft 
thrombosis and significantly delay rejection.  The results confirm a pivotal role for thrombin in 
AMR in vivo. This approach targets donor organs rather than the recipient and is intended to be 
directly translatable to clinical use.  
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Introduction  
The modification of pharmacologically active agents by specific attachment of generic 
“cytotopic” reagents based on the myristoyl-electrostatic switch (1) has been described elsewhere 
(2). The term “cytotopic” is used in this paper to mean a chemically modified agent that acts 
primarily at the surface (topos) of a cell (cytos).  The approach has found particular use with 
regulators of complement activation, notably fragments of CR1 (CD35) (3), CD55 (4) and CD59 
(5). Cytotopic membrane-localising groups are relatively hydrophilic despite containing at least 
one membrane-insertive alkanoyl group and conjugates of active agents with such groups remain 
sufficiently water-soluble to be used as (bio)pharmaceuticals (2). Furthermore, such agents can 
be applied locally to organs or tissues where they are retained and function in a regioselective 
fashion.  
 
Experimental and clinical experience with the CR1 derivative Mirococept (APT070) has shown 
that this agent can be delivered to kidneys (6, 7) and in one case, human liver (8) by ex-vivo 
perfusion resulting in uptake by the microvasculature of the organ and a consequent enhanced 
complement inhibitory activity upon reperfusion of the implanted graft. The process of antibody-
mediated rejection (AMR) not only involves complement activation, but also the direct effects of 
high levels of anti-donor MHC Class I and Class II antibodies, which activate donor endothelium 
promoting intravascular thrombosis; in the florid form seen in hyperacute AMR, this can cause 
graft necrosis.  
 
Detailed histological evaluation of large animal cardiac allo- and xenografts (and human 
allografts) undergoing AMR suggests that this thrombotic process, beginning in venules, is a very 
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early feature of the rejection process (9). In AMR associated with blood group-incompatible renal 
transplantation, it was evident that glomerular fibrin deposition was a very early manifestation of 
humoral rejection, appearing before graft dysfunction in some cases (10). The major benefit of 
inhibiting thrombin generation after xenotransplantation was shown by our group several years 
ago using transgenic mouse hearts transplanted into rats, following which the manifestations of 
AMR were completely abolished, though notably the hearts were still susceptible to cell-
mediated rejection (11).  In xenografts, this phenomenon can arise because xenogeneic 
endothelial cells are capable of direct conversion of prothrombin to active thrombin (12, 13), the 
central protein in the coagulation cascade triggered via a number of different mechanisms, 
independently of AMR (14).  There are indications that similar complement-independent 
thrombosis plays a prominent role in rodent AMR models, promoted by molecules such as fgl-2 
(15, 16) suggesting that targeting coagulation processes directly inside allografts might have 
similar impact as we have shown in xenografts.  We were therefore interested in generating 
cytotopic anticoagulants, particularly thrombin inhibitors, for use inside organs, specifically to 
inhibit thrombin generation after transplantation.  
 
In order to target coagulation we constructed a membrane-associated anticoagulant based on a 
minimized form of hirudin, (a well known thrombin inhibitor, naturally occurring in the salivary 
glands of leeches). The principle behind the resulting synthetic cell-tethered inhibitor 
(Thrombalexin, TLN-1) is similar to the complement inhibitor Mirococept (2, 3). TLN-1 binds 
the phospholipid bilayer using a combination of a bis-myristoyl hydrophobic structure (5) and a 
lysine-rich sequence, which binds negatively charged phospholipid headgroups. TLN-1, like 
hirudin and its synthetic derivative Hirulog, interacts with thrombin at the active site and at the 
fibrinogen-binding exosite I (17). 
5 
 
In this study, we report the generation and evaluation of TLN-1 in an appropriate rodent model of 
AMR, testing the hypothesis that treatment of the donor organ with a membrane localizing 
biological inhibitor of thrombin could prevent the key manifestations of AMR, increasing graft 
survival, improving renal function and reducing renal tissue injury.  
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Materials and Methods 
Animals  
All animals were purchased from Charles River (Kent, UK). Animals used in this project were 
inbred male DA (RT1a) rats, weighing approximately 150g, used as skin and kidney donors. 
Inbred male Lewis (RT1i) rats, weighing approximately 200g, were used as recipients. Animals 
had free access to standard rat chow and water. All procedures were carried out in accordance 
with a UK Home Office license for animal experimentation.  
Skin Transplantation  
Based on a method from Guttman (18), Lewis recipients were pre-immunised by sequential 
grafting of three full thickness tail skin segments (~2 cm2) from DA donors. The skin grafts were 
held in place by applying a skin adhesive gel (Germolene New Skin, Boots,UK) and bandaged 
for seven days, after which the bandages were removed. The first two skin transplants were 
separated by a two-week interval, followed by a four-week period (to allow Ig affinity 
maturation). 7-10 days after the third skin graft, the Lewis recipients received a DA kidney graft.  
Rat Renal Transplantation 
Rat renal transplantation was carried out as described previously (7). The donor and the recipient 
preparations took place simultaneously thus minimizing the period of donor organ ischemia. 
Bilateral native nephrectomies were performed, making the survival of the recipient dependent 
only on the transplanted kidney. Graft rejection was defined either by elevated BUN (≥40 mM), 
or signs of poor health necessitating termination of the experiment, or spontaneous death of an 
animal, all accompanied by histological evidence of rejection.  
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Therapeutic Agents  
TLN-1 (also called PTL004) contains the two thrombin binding sites of Hirulog-1, a structurally 
minimized form of the leech anticoagulant hirudin (17). This was modified by adding a C-
terminal extension to locate a thiol-containing cysteine linker for conjugation at a point distant 
from either of the two thrombin binding sites to create the peptide we have called ‘HLL’. This is 
used as a non-cytotopic, thrombin-binding agent in some experiments. HLL has the sequence  
[D-Phe-L-Pro-L-Arg-L-Pro-Gly-Gly-Gly-Gly-L-Asp-Gly-L-Asp-L-Phe-L-Glu-L-Glu-L-Ile–L-
Pro-L-Glu-L-Glu-L-Tyr-L-Leu-Gly-Gly-L-Cys-amide]. HLL was then conjugated with the 
cytotopic tail APT3146  [(N-alpha, N-epsilon Bis-myristoyl Lys-Ser-Ser-Lys-Ser-Pro-Lys-Lys-
Asp-Asp-Lys-Lys-Pro-Gly-Asp-(S-2-pyridyldithio) Cys], mediated by disulfide interchange (5). 
The conjugate has a mass of 4649 Daltons by time-of-flight mass spectrometry and was prepared 
by reaction of the two components in aqueous solution at pH ~7.4 followed by further 
purification (19). The component peptides were prepared using solid phase synthesis by 
Cambridge Research Biochemicals, Billingham, UK (both components were also synthesized at 
scale by Almac Sciences, Craigavon, UK). Later variants of TLN have been prepared using 
different bridging chemistry and will be described elsewhere. 
 
Inhibitory activity of TLN-1 against human thrombin in solution and when tethered to 
cells. 
Human plasma thrombin (T6884) and N-p-5 Tosyl-Gly-Pro-Arg-pnitroanilide (T1637-substrate) 
were obtained from Sigma-Aldrich (Gillingham, UK). Stock solutions of 10U/ml and 1mM 
(respectively) were prepared in 0.05M Tris-HCl, pH 7.5, 0.1M NaCl and 0.5% BSA (20). 
Reaction mixtures were prepared with buffer, thrombin (5ul, 0.05U) and substrate (100ul, 
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125nM) to a final volume of 800ul and incubated at 25 °C. When TLN-1 (or control HLL) were 
included (at various doses), these were premixed with thrombin at 25 °C for ~7min and the 
reaction was then initiated by addition of substrate. Thrombin-catalyzed hydrolysis of N-p-Tosyl-
Gly-Pro-Arg-p-nitroanilide was monitored at 405nm on a Spectramax Plus384 (Molecular 
Devices, Sunnyvale CA,10 USA). The velocity of thrombin-catalyzed reaction was plotted 
against substrate concentration values using GraphPadPrism5 software and fitting data with non-
linear data matching option. For each substrate concentration assayed, the velocity of the enzyme 
reaction represented the slope of the linear phase, expressed as amount of product formed per 
time (A405 vs time). The KM of Thrombin for N-p-Tosyl-Gly-Pro-Arg-p-nitroanilide substrate 
under these conditions was found to be 10.47 + 2 nM. 
Guinea Pig red blood cells (RBC) washed with gelatin-veronal buffer (GVB) were incubated 
with TLN-1 (or HLL control) for 10min at RT with gentle agitation. After several washes, the 
supernatant was discarded and the cell pellet resuspended with GVB and thrombin in a final 
reaction volume of 460 ul. Cells were further incubated for 3min at 37°C in a water bath before 
being gently pelleted by centrifugation and counted by microscopy. Thrombin activity in the 
supernatant was assessed as above by addition of T1637-substrate. Values were expressed as 
percentage of cell inhibition for a certain thrombin amount after subtracting values of HLL-
treated cells and normalization for cell number. 
 
Plasma re-calcification assay 
1.5 x 105 human CD34-derived progenitor cells (21) (kind gift of N Levicar, Hammersmith 
Hospital) were suspended in 50 μl Tris-buffered saline and mixed with 100μl of normal human 
plasma (Sigma) in glass tubes (Corning, NY, USA). 100µl of 25mM CaCl2 in Tris-buffered saline 
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was added and the tube incubated at 37°C in a water bath - the time for a fibrin clot to form was 
determined in triplicate, during which time the tubes were continuously agitated by tilting. In 
some assays, cells were incubated with 200uL of HLL or TLN-1 for 25 30min at 4°C before 
washing twice and inclusion in the clotting assay. 
 
In-Situ Perfusion with TLN-1 
Intra-renal perfusion with TLN-1 (2μM) was based on a previously described protocol (6).  TLN-
1 was dissolved in 5ml of Soltran perfusion solution (Baxter Healthcare Ltd, UK) perfused into 
the renal artery (1ml/min over 5 minutes) and left to dwell for ten minutes before flushing with 
5ml of Soltran to wash out unbound TLN-1. The donor kidney was then excised and immediately 
transplanted into the recipient. Any bleeding from the anastomosis was controlled by Surgicel 
absorbable haemostat (Ethicon, Somerville, NJ, USA) and gentle pressure.  
 
Collection of Blood and Extraction of Serum  
Blood samples were collected before and after renal transplantation at appropriate time points by 
tail vein sampling. For serum preparation, whole blood was centrifuged twice for 15 minutes at 
14000 rpm. Serum samples taken prior to renal transplantation were used to assess alloantibody 
titre. Post-transplantation, renal function was assessed by daily estimation of blood urea nitrogen 
(BUN) using a standard urease kit (BUN Infinity, Fisher Scientific, Loughborough, UK), 
following the manufacturer’s instructions. Terminal blood samples were collected by cardiac 
puncture.  
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Rat splenocyte extraction 
Rat splenocytes were obtained by disruption of fresh spleen through a 70μm sieve into sterile 
PBS. The cells were centrifuged and incubated with 5 ml of RBC lysis buffer for 5 minutes on 
ice. Lysis was stopped by adding PBS/ 2% FCS. The spleen cells were either resuspended in 
RPMI 1640 (Sigma) or frozen in DMSO (Sigma) in cryogenic vials (Nalgene, UK) and stored in 
liquid nitrogen.  
  
Detection of Alloreactive IgG   
DA splenocytes were aliquoted (1x106/well) into 96 v-well bottom plates, pre-blocked with 50μl 
of PBS/2% BSA containing 20% normal mouse serum and left on ice for 20 minutes. For gating 
of T-cells for flow cytometric analysis, mouse anti-rat CD3-PE (clone G4.18, eBioscience Ltd) 
was added to the splenocytes and incubated on for 20 minutes. Serum samples from sensitized 
recipients were then added at final dilutions of 1:10, 1:50, 1:250, 1:1250 and 1:6250 subsequently 
incubated as before. Splenocytes were washed twice with PBS/2% BSA then incubated with 
mouse anti-rat IgG-FITC (H+L, eBioscience Ltd,) for 20 minutes on ice. Cells were then washed 
twice and fixed in 2% paraformaldehyde before being analysed on a FACScan flow cytometer 
(Becton Dickinson).  
 
11 
Assessment of Renal Pathology 
Transplanted kidneys removed at appropriate time points were transferred to 4% 
paraformaldehyde. Paraffin-embedded tissue was cut into 2μm sections and stained with Martius 
Scarlet Blue (MSB).  
 
Statistical Analyses 
Values were compared using Student’s t test. Survival curves were compared using a log-rank 
test, and depicted using Kaplan-Meier plots. A difference was considered significant when 
p<0.05. 
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Results  
TLN-1 exhibits membrane-localised inhibition of thrombin and clotting. 
The structure of TLN-1 is shown in Fig. 1A.  Guinea Pig RBC were incubated in a solution of 
TLN-1 (1µM), during which TLN-1 was absorbed onto the RBC surface, so that after washing, 
the RBC were able to specifically remove 0.05U of exogenously added thrombin from solution 
(Fig. 1B). In contrast, RBC incubated with control HLL peptide (see methods) bound no active 
HLL, such that after washing the RBC were unable to absorb any thrombin.  Evidence of non-
specific interaction of thrombin with RBC membrane was not detected in these experiments (data 
not shown). Dose titration of thrombin revealed that 1µM TLN-1 applied to RBC could remove 
80% of 0.4U exogenously added thrombin, whereas dose titration of TLN-1 on the RBC revealed 
that 0.1µM removed 84% of 0.05U thrombin (data not shown). These data allowed the 
calculation of a thrombin inhibitory capacity of about 90% for 0.1U/104 cells exposed to1 µM 
TLN-1 (typically 1-2 units of thrombin will clot 1 mL of plasma). 
The functional importance of this interaction between TLN-1 and cell membranes is shown in 
Fig. 1C.  Human CD34+ progenitor cells significantly reduced the clotting times of re-calcified 
human plasma (by virtue of the fact that they expressed human TF (data not shown)), compared 
to the clotting times observed in glass tubes when no cells were present. Pre-incubation of cells 
with TLN-1, followed by washing, completely abolished this pro-coagulant activity, but did not 
inhibit clotting induced by the glass tubes. In contrast, HLL used in equimolar amounts as the 
TLN-1 and added to the clotting assay, caused significant inhibition of all clotting activity, not 
just that associated with the presence of the CD34+ cells.   
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These data show that TLN-1 binds avidly to cell membranes, binds thrombin and removes it from 
solution, and exhibits anticoagulant activity selectively at the surface of cells to which it has 
bound.  
 
 
Impact of TLN-1 on intragraft thrombosis and graft survival in a sensitised rat renal 
allograft model of AMR. 
 
Flow cytometric assessment of DA splenocytes incubated with serum from Lewis rats sensitized 
by three DA skin grafts revealed high levels of circulating anti-DA IgG (data not shown). These 
pre-sensitised animals rejected unmodified DA renal allografts with a median survival time 
(MST) of 1.8 days, compared to control non-sensitised Lewis rats, which rejected with a MST of 
5.6 days (Fig. 2A).   
Perfusion of DA kidneys pre-transplantation with Soltran alone had no impact on survival time 
(Fig. 2B) and rat recipients of these kidneys developed a rapid rise in BUN (Fig. 2C&D).  
Histology of kidneys harvested at time of rejection revealed florid features of AMR, with 50% of 
glomeruli demonstrating thrombosis (Fig. 3 and 4), significant interstitial haemorrhage and 
infarction of tubules (Figs. 3&5) and a prominent neutrophil peritubular capillaritis (Fig. 5).  
In contrast, perfusion of DA kidneys pre-transplantation with TLN-1 caused a significant 
prolongation of graft survival, similar to that seen in non-sensitised animals (Fig. 2B), associated 
with a delayed increase in BUN (Fig. 2C&D). Histology of rejected kidneys showed a prominent 
cellular infiltrate, in contrast to the paucity of cells seen in Soltran-perfused kidneys (Figs. 3&4), 
and although there were signs of AMR in TLN-1 kidneys, including a marked peritubular 
capillaritis (Fig. 5), the proportion of glomeruli showing thrombosis was reduced and the 
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thrombosis seen tended to be segmental (Fig. 4). With the application of local methods of 
haemostasis (see methods), there was no evidence of bleeding from the anastomosis in any of the 
TLN-1-treated grafts, nor of any systemic bleeding tendency in recipients of TLN-1-treated 
organs. 
 
These data indicate that pre-perfusion of transplanted kidneys with TLN-1 has a significant 
impact on the mode and timing of rejection in these highly sensitized rats, characterized by 
inhibition of thrombosis and prevention of infarction, thus allowing time for significant cellular 
infiltration and the onset of cell-mediated rejection. 
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Discussion 
 
The results presented here demonstrate that a novel compound generated by conjugating a potent 
direct thrombin inhibitor to a membrane-localizing entity is capable of binding to cell 
membranes, on which it can selectively capture (and inactivate) thrombin from the milieu and 
inhibit any procoagulant properties of the cell surface, without apparent impact on clotting 
induced beyond the antithrombin-treated cell surface. Moreover perfusion of rodent kidney grafts 
prior to transplantation endowed them with a resistance to the manifestations of AMR, without 
any overt features associated with systemic anticoagulation. In particular, the impact on intragraft 
thrombosis was substantial, both in terms of the number of glomeruli that displayed no 
thrombosis and in the amount of thrombus in that minority of glomeruli with thrombosis. Graft 
survival was extended to that seen in non-sensitised individuals and was accompanied by a 
significant cellular infiltrate and extensive tubulitis, consistent with the perception that cell-
mediated immune mechanisms contributed to rejection in TLN-1 treated organs. 
These results are reminiscent of those we presented previously (11), using a non-sensitised 
xenogeneic model system in which membrane tethered anticoagulants were expressed 
transgenically on the endothelium of mouse hearts transplanted into rats. Those hearts were 
rejected by cell-mediated mechanisms despite the presence of high titre anti-mouse antibodies 
and were completely resistant to intravascular thrombosis, consequent upon sustained and stable 
expression of a hirudin-based construct by graft endothelial cells. In these new experiments, the 
effective residence time of TLN-1 on the graft endothelium is probably ~24 hours (unpublished 
data), so it is surprising that the functional impact was so marked, but it illustrates the clinical 
therapeutic potential of TLN-1 (and later derivatives, unpublished) in situations where a human 
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donor organ is at risk of thrombosis, including after desensitisation to remove donor specific 
HLA antibodies. 
 
Thrombin plays an important role in AMR, not only via generation of fibrin to form occlusive 
thrombus, but also through other mechanisms, including amplification of the complement 
cascade via several different routes (22, 23) and direct activation of graft endothelial cells via 
protease-activated receptor signaling (24), which has been shown to be important for local 
chemokine gradient generation and leukocyte recruitment in the context of AMR (25). Effective 
control of these non-thrombotic manifestations of thrombin are difficult to achieve using 
systemic anticoagulants, because of the risk of bleeding associated with the high doses required 
to maintain inhibition of coagulation proteases at cell membranes (26). Our approach of tethering 
high concentrations of anticoagulant at the endothelial surface overcomes this potential problem, 
and it is noteworthy that our results were achieved without significant bleeding from the surgical 
anastomoses, although local measures including surgical dressings and pressure were necessary.  
Studies addressing the impact of TLN-1 on complement activation and protease activated 
receptor signaling will be reported elsewhere.  
 
In summary, the data presented here show that loading of the donor kidney with the novel 
membrane-adherent anti-thrombin TLN-1 can prevent thrombosis of the graft vasculature without 
the need for systemic anticoagulation. TLN-1 and its method of use are both translatable to 
clinical investigation and our current work involves developmental chemistry and toxicology 
studies to enable subsequent evaluation in phase 1 and 2 studies involving transplant patients at 
high risk of thrombosis. We envisage that transplant surgery performed using a functionally 
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anticoagulated organ without inducing a coagulation defect in the recipient would represent a 
significant medical advance. In a markedly pro-thrombotic environment, the risk of graft 
thrombosis will therefore be significantly reduced, at least for the likely duration that the tailed 
anticoagulant remains on the surface of the endothelial cell.  
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Figure Legends 
Figure 1: Structure function of TLN-1 
A: Structure of TLN-1 showing the thrombin-binding domain (HLL-upper) and cytotopic (lower) 
component of the agent. 
B:  Depletion of thrombin from solution by guinea pig red blood cells incubated with TLN-1 
(squares) or HLL (diamonds), before washing, followed by assay of the amount of residual 
thrombin still present in the supernatant, measured by amidolytic activity using N-p-5 Tosyl-Gly-
Pro-Arg-pnitroanilide. 
C:  Clotting times of human re-calcified plasma in glass tubes (‘No cells’), in the presence of 
tissue factor-expressing human CD34 cells (‘Cells alone’), in the presence of TLN-1-coated 
human CD34+ cells (‘TLN-1 coated’) or with human CD34+ cells and HLL in the clotting assay.  
 
Figure 2 Impact of TLN-1 on renal allograft survival.  
A: Actual survival curve following transplantation of DA kidneys into sensitised and non-
sensitised Lewis rats. Non-sensitised recipients (n=6) rejected the allogeneic kidneys with a 
median survival time (MST) of 5.6 days. Recipients pre-sensitised with three DA skin grafts 
(n=6), rejected kidneys with a MST of 1.8 days. 
B: Actual survival curve following transplantation of DA kidneys into sensitized Lewis rats. 
Control allografts perfused with Soltran pre-transplantation (n=4) rejected kidneys with a MST of 
1.5 days.  Allografts perfused with Soltran-containing TLN-1 pre-transplantation (n=6) showed a 
statistically significant prolongation of survival to 5.1 days.  
C: Dynamic changes in renal function post transplantation. Plot of daily BUN estimations from 
rats in B receiving Soltran-perfused (dotted lines) or Soltran+TLN-1treated grafts (solid line). 
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D: Mean (± SEM) day 1 BUN values from Soltran (black bar) vs. Soltran+TLN-1 (white bar) 
perfused allografts illustrating statistically significant differences in renal function at this time 
point. 
 
Figure 3: Histology from allografts perfused with Soltran vs. Soltran+TLN-1 
Representative sections from Soltran (A-C) or Soltran containing TLN-1-perfused (D-F) DA 
kidney allografts harvested on day of rejection. All stained with MSB to highlight fibrin (red) and 
erythrocytes (yellow) taken at x100 magnification.  
A-C: Illustrating thrombosis (black arrows) in 3/5 (A), 4/6 (B) and 4/5 glomeruli (C). Sections 
also illustrate tubular necrosis, interstitial haemorrhage and polymorphs in peritubular capillaries 
(area defined by elipse in B).  
D-F: Illustrating thrombosis (black arrows) in 0/4 (D), 1/4 (E) and 2/4 glomeruli (F).  Sections 
also illustrate extensive cellular infiltrate (white arrows in E), interstitial haemorrhage (yellow 
arrow F) and tubular infarction (blue arrow F).  
 
Figure 4 Glomerular thrombosis seen in from allografts perfused with Soltran vs. 
Soltran+TLN-1 
Representative sections from Soltran (A-C) or Soltran-containing TLN-1-perfused (D-F) DA 
kidney allografts harvested on day of rejection. All stained with MSB to highlight fibrin thrombi 
(red) and erythrocytes (yellow) and taken at x400 magnification.  
A-C: Representative glomeruli from majority (A,B thrombosed) and minority (C) of kidneys 
perfused with Soltran alone. Examination of 10 low power fields per section revealed average of 
53% of glomeruli contained thrombus. 
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D-F: Representative glomeruli from majority (D, E- non-thrombosed) and minority (F) of 
kidneys perfused with Soltran containing TLN-1. Examination of 10 low-power fields per section 
revealed average of 24% of glomeruli contained thrombus. 
 
Figure 5 Inflammatory lesions in from allografts perfused with Soltran vs. Soltran+TLN-1.  
Representative sections from Soltran (A,B) or Soltran containing TLN-1-perfused (C,D) DA 
kidney allografts harvested on day of rejection. All stained with MSB and taken at x100 (A, C) or 
x200 (B,D) magnification. 
A&B: Illustrating the lack of significant interstitial infiltrate but prominent tubular necrosis (A) 
and extensive polymorphonuclear leukocytic peritubular capillaritis (area defined by elipse in B). 
C: Illustrating the significant cellular lesions manifesting as tubultis (black arrows), glomerulitis 
(white arrow) and peritubular capillaritis (red arrows). 
D: Higher power image to illustrate the peritubular capillaritis (red arrows). 
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